Nicotine

Nicotine gum/lozenge at 2-4 mg has real, A-tier cognitive evidence (Heishman 2010 meta: fine motor, alerting attention, episodic memory in non-smokers, small-medium ES). But Dylan is 20 with prefrontal cortex still myelinating through ~25, and adolescent nicotine exposure has lasting attention/impulse changes in both rat and human-epi data. Dependence risk + adolescent-brain risk + the existence of cleaner PRN alternatives (caffeine + theanine, modafinil, tyrosine) means WATCH-LIST, not daily. If used at all: 2 mg gum PRN absolute max 1-2×/week, never paired with cue-conditioning context (no "morning routine" anchoring, no "before social call" anchoring), gum/lozenge route only (NEVER vape/pouch — both cue-conditioning death traps), and pre-commit to a hard stop after 8 weeks for a re-evaluation.

Nicotine is a neuronal nicotinic acetylcholine receptor (nAChR) agonist acting at multiple subtypes with different distributions and behavioral roles:

α4β2 nAChR (the dominant CNS subtype, ~80% of brain nAChRs):

• High-affinity for nicotine; concentrated in thalamus, cortex, striatum, ventral tegmental area (VTA).
• Mediates the bulk of nicotine's alerting + attention + mild-reward + dependence-forming effects.
• VTA α4β2 activation → mesolimbic dopamine release in nucleus accumbens → the reward signal that drives dependence. This is the receptor that makes nicotine addictive.
• Cortical/thalamic α4β2 activation → improved attentional gating, faster reaction time, better signal-to-noise in cognitive tasks.

α7 nAChR:

• Lower affinity for nicotine, broader desensitization profile.
• Concentrated in hippocampus, cortex, peripheral immune cells (cholinergic anti-inflammatory pathway).
• Mediates memory encoding (especially episodic), anti-inflammatory signaling via the vagal cholinergic axis, neuroprotective signal in some preclinical models.
• Tropisetron and other α7-selective compounds attempt to capture this benefit without α4β2-mediated dependence — see [tropisetron] entry.

α3β4 nAChR:

• Concentrated in autonomic ganglia + adrenal medulla.
• Mediates the peripheral cardiovascular + GI effects: HR rise, BP rise, sympathetic activation, nausea (medullary chemoreceptor zone), GI motility.
• This is the receptor responsible for the "first-cigarette nausea" that habituates within hours.

Pharmacological signature — rapid desensitization is itself part of the effect:

• Nicotine binds nAChRs and triggers conformational change → channel opens (Na+/Ca2+ influx → depolarization → neurotransmitter release downstream) → within milliseconds-to-seconds the receptor desensitizes (channel closes despite continued nicotine binding).
• Net acute effect = brief activation + prolonged desensitization. This is why nicotine has paradoxical "stimulant + anxiolytic" subjective profile — the alerting comes from the brief activation; the calming/anxiolytic feel comes from the desensitization phase reducing baseline cholinergic tone.
• At low doses (gum 2 mg, lozenge 2 mg), the activation phase dominates → alertness + attention. At high doses (smoking a pack, high-dose patch in naive user), desensitization dominates → "smoker's calm" + tolerance.

Downstream neurotransmitter cascade:

• Dopamine (via VTA α4β2 → NAc): mild reward, motivation, focus reinforcement. This is the addiction substrate.
• Acetylcholine (via cortical α4β2 + α7): direct cognitive enhancement on cholinergic-dependent tasks (working memory, episodic memory, attention).
• Norepinephrine (via locus coeruleus + sympathetic activation): alertness, peripheral cardiovascular effects.
• Glutamate (presynaptic α7 facilitation): improved cortical signal-to-noise.
• GABA (via interneuron α4β2): mild anxiolytic at low doses.

Why the cognitive effect is real but bounded:

• The α4β2 + α7 cognitive signal at gum 2-4 mg is a genuine cholinergic + dopaminergic enhancement — comparable in magnitude to mid-range caffeine on attention tasks.
• The dependence signal at the same dose is nonzero and compounds with cue-conditioning (the "I associate nicotine with X reward" pairing). This is what differentiates nicotine from caffeine — caffeine's reward signal is much weaker, so dependence is mild and physical-only; nicotine's reward signal is strong enough that psychological dependence forms even in users who never smoked.